The approval of Onyda XR makes it the first non-stimulant liquid medication for attention-deficit hyperactivity disorder to be marketed in the United States.
FDA approves Tris Pharma’s Onyda XR, a once-daily extended-release oral suspension for the treatment of ADHD
Leave a comment
